Literature DB >> 15908830

Stimulant-atypical antipsychotic interaction and acute dystonia.

Eric Benjamin, Sara Salek.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15908830     DOI: 10.1097/01.chi.0000159166.96967.13

Source DB:  PubMed          Journal:  J Am Acad Child Adolesc Psychiatry        ISSN: 0890-8567            Impact factor:   8.829


× No keyword cloud information.
  6 in total

1.  The dopamine dilemma: using stimulants and antipsychotics concurrently.

Authors:  Jason Yanofski
Journal:  Psychiatry (Edgmont)       Date:  2010-06

2.  Trends in psychotropic polypharmacy among youths enrolled in Ohio Medicaid, 2002-2008.

Authors:  Cynthia A Fontanella; Lynn A Warner; Gary S Phillips; Jeffrey A Bridge; John V Campo
Journal:  Psychiatr Serv       Date:  2014-10-31       Impact factor: 3.084

3.  The use of medication against attention deficit/hyperactivity disorder in Denmark: a drug use study from a patient perspective.

Authors:  Anton Pottegård; Bine Kjøller Bjerregaard; Dorte Glintborg; Lisbeth Sandal Kortegaard; Jesper Hallas; Søren Ilsøe Moreno
Journal:  Eur J Clin Pharmacol       Date:  2012-07-19       Impact factor: 2.953

4.  Movement disorders and use of risperidone and methylphenidate: a review of case reports and an analysis of the WHO database in pharmacovigilance.

Authors:  Dominik Stämpfli; Stefan Weiler; Andrea M Burden
Journal:  Eur Child Adolesc Psychiatry       Date:  2020-07-03       Impact factor: 4.785

5.  Acute Hyperkinetic Movement Disorders as a Multifactorial Pharmacodynamic Drug Interaction Between Methylphenidate and Risperidone in Children and Adolescents.

Authors:  Mohamed Mohamoud; Qi Chen; David Croteau; Carmen Cheng; Keith Burkhart; Donna A Volpe; Cindy Kortepeter; Dorothy Demczar; Marc Stone
Journal:  J Clin Psychopharmacol       Date:  2022 May-Jun 01       Impact factor: 3.118

6.  Dystonia in an adolescent on risperidone following the discontinuation of methylphenidate: a case report.

Authors:  Gulen Guler; Veli Yildirim; Meryem Ozlem Kutuk; Fevziye Toros
Journal:  Clin Psychopharmacol Neurosci       Date:  2015-04-30       Impact factor: 2.582

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.